💬In plain words
What the trial is, and whether it could suit you
The goal of this study is to understand how light sensitivity in the eye affects sleep, mood, alertness, and cognition in adults with glaucoma compared to healthy individuals aged 45-75 years.
The main questions it aims to answer are:
1. Do patients with glaucoma experience poorer sleep, mood, alertness, and cognitive function than age-matched healthy adults?
2. Are these changes related to reduced light sensitivity in special retinal cells called intrinsically photosensitive retinal ganglion cells (ipRGCs), lost in glaucoma?
3. Can exposure to safe, full-spectrum indoor light help improve these functions?
Researchers will compare patients with glaucoma and age-matched healthy controls to see if differences in light sensitivity can explain changes in non-visual light responses (i.e., sleep, mood, alertness, and cognition) and whether full-spectrum light exposure can enhance alertness
Sign in to get the eligibility rules as simple questions to take to your doctor.
📋 Eligibility rules (as published)
Inclusion Criteria:
* Patients with glaucoma must meet all of the inclusion criteria to participate in this study.
* Patients diagnosed with primary open-angle glaucoma (POAG), as indicated by Humphrey Visual Field (HVF) mean deviation (VFMD) scores better than -12 dB in at least one eye during their most recent clinic visit.
* Patients having spared central vision.
* Patients aged 45 to 75 years old.
* Patients with a best-corrected visual acuity better than 6/12
* English-speaking patients
Healthy controls must meet all of the inclusion criteria to participate in this study:
* Participants aged 50 to 70 years old.
* Participants with a best-corrected visual acuity better than 6/12
* Normal ophthalmic examination
* English-speaking participants
Exclusion Criteria:
* All subjects (patients and controls) meeting any of the exclusion criteria at baseline will be excluded from participation:
* Participants with myopia exhibiting a refractive error exceeding -8.00 diopters (D)
* Participants with a history of complicated previous intraocular surgery
* Participants taking alpha-adrenergic agonist eye drops or other systemic medications or drugs that could affect the pupillary response
* Participants with any past or current ocular condition (i.e., age-related retinal diseases (e.g., age-related macular degeneration), retinal pigment epithelium diseases (e.g., Best's disease), diabetic retinopathy, or other optic or generalized neuropathies, significant ocular trauma, or any eye condition affecting fixation (eg. Nystagmus)).
* Participants diagnosed with cataracts at NS3+ (Nuclear Sclerosis) and above, as well as those with Posterior Subcapsular (PSC) cataracts
* Participants with clinically diagnosed psychiatric or neurologic disorders, including cognitive impairment or dementia
* Participants with diagnosed mood disorders
* Participants engaged in night shift work within the past three months, are currently using sleeping pills, or have recently travelled across timezones within a month prior to the study
* Participants with obstructive sleep apnea
* Participants with abnormal auditory function
* Participants with impaired color vision
* Pre-menopausal women (last menstrual period \< 1 year) (If applicable)
* Patients having unilateral glaucoma, congenital glaucoma, non-glaucomatous optic neuropathy, abnormal central vision
* Diabetics on treatment
HealthTeky